Populationsfarmakokinetiske analyser hos patienter med pulmonal arteriel hypertension tyder på, at samtidig anvendelse af beta- blokkere i kombination med CYP3A4- substrater kan resultere i en øget sildenafil- eksponering sammenlignet med anvendelse af CYP3A4- substrater alene.
The population pharmacokinetic analysis in pulmonary arterial hypertension patients suggested that co-administration of beta-blockers in combination with CYP3A4 substrates might result in an additional increase in sildenafil exposure compared with administration of CYP3A4 substrates alone.